Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

Sanofi's next big move official

Posted 27 March 2024 AM

Sanofi is officially looking to crack a new market for its blockbuster Dupixent in Australia with the TGA offering the priority review pathway for chronic obstructive pulmonary disease (COPD).

Dupixent, a monoclonal antibody that inhibits the signalling of IL-4 and IL-13 pathways, is already TGA approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and prurigo nodularis.

To see the whole article, please login

Popular

Is 2024 the Year of Burnout?
Albo puts hand up for pharma selfie
Why pharma redundancies hurt
Top specialist in Deep Fake scam
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home